Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.546    -0.034 (-5.86%)
Bid:
0.55
Ask:
0.60
Spread: 0.05 (9.091%)
Market Cap: £3.17m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

AGM Statement

24 Jun 2019 16:42

RNS Number : 2473D
Futura Medical PLC
24 June 2019
 

Results of Annual General Meeting

24 June 2019

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology currently focused on sexual health and pain, announces that at its Annual General Meeting, held earlier today, all resolutions were duly passed by the shareholders.

 

For further information please contact:

Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.comTel: +44 (0) 1483 685 670

Nominated Adviser and Sole Broker:LiberumBidhi Bhoma/ Euan Brown/ Kane CollingsTel: +44 (0) 203 100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 950 9144

 

Notes to editors:

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

 

The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension. FM57 is progressing on track, with headline data expected by the end of 2019.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGCKQDNPBKDFAB
Date   Source Headline
13th Dec 20199:05 amRNSSecond Price Monitoring Extn
13th Dec 20199:00 amRNSPrice Monitoring Extension
10th Dec 20194:40 pmRNSSecond Price Monitoring Extn
10th Dec 20194:35 pmRNSPrice Monitoring Extension
10th Dec 201911:05 amRNSSecond Price Monitoring Extn
10th Dec 201911:00 amRNSPrice Monitoring Extension
10th Dec 20199:05 amRNSSecond Price Monitoring Extn
10th Dec 20199:00 amRNSPrice Monitoring Extension
10th Dec 20197:00 amRNSTop Line Results from MED2005 Phase 3 study
6th Dec 20194:10 pmRNSBlock Listing Six Monthly Return
22nd Nov 201911:48 amRNSHolding(s) in Company
20th Nov 20194:05 pmRNSHolding(s) in Company
20th Nov 20194:04 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSPublishes Fireside Chat with Prof Wayne Hellstrom
11th Nov 201912:44 pmRNSHolding(s) in Company
29th Oct 201910:03 amRNSHolding(s) in Company
28th Oct 20194:12 pmRNSMED2005 Safety and Efficacy Data Reported at SMSNA
23rd Oct 201912:46 pmRNSChange of Auditor
21st Oct 20197:00 amRNSFinal Dosing of Last Patient in MED2005 Ph3 study
15th Oct 20195:44 pmRNSFutura Medical to Present Data on MED2005 at SMSNA
15th Oct 20195:42 pmRNSDirector / PCA Shareholding
18th Sep 20195:42 pmRNSDirector/PDMR Shareholding
16th Sep 201910:11 amRNSHolding(s) in Company
13th Sep 20194:40 pmRNSSecond Price Monitoring Extn
13th Sep 20194:35 pmRNSPrice Monitoring Extension
13th Sep 201911:46 amRNSHolding(s) in Company
12th Sep 20199:05 amRNSSecond Price Monitoring Extn
12th Sep 20199:00 amRNSPrice Monitoring Extension
11th Sep 20194:40 pmRNSSecond Price Monitoring Extn
11th Sep 20194:35 pmRNSPrice Monitoring Extension
11th Sep 20197:00 amRNSInterim Results for Six Months ended 30 June 2019
10th Sep 20197:00 amRNSFutura Announces Joint Venture Collaboration
16th Aug 20194:37 pmRNSHolding(s) in Company
12th Aug 20193:21 pmRNSDirector/PDMR Shareholding
12th Aug 20197:00 amRNSNotice of Interim Results
23rd Jul 20192:06 pmRNSSecond Price Monitoring Extn
23rd Jul 20192:00 pmRNSPrice Monitoring Extension
5th Jul 20193:54 pmRNSHolding(s) in Company
28th Jun 20194:40 pmRNSSecond Price Monitoring Extn
28th Jun 20194:36 pmRNSPrice Monitoring Extension
25th Jun 20194:47 pmRNSDirector/PDMR Shareholding
24th Jun 20194:42 pmRNSAGM Statement
24th Jun 20197:00 amRNSAGM Statement
19th Jun 20197:00 amRNSRecruitment completed for MED2005 Phase 3 study
30th May 20197:00 amRNSNotice of AGM
30th May 20197:00 amRNSBlock listing Interim Review
29th May 201910:47 amRNSHolding(s) in Company
23rd May 20197:00 amRNSLiberum Appointed as Nominated Adviser & Broker
8th May 20192:05 pmRNSSecond Price Monitoring Extn
8th May 20192:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.